Drug Type Chemical drugs |
Synonyms Boxol, Dalteparin sodium (JAN/USP/INN), Fragmine + [14] |
Target |
Action inhibitors |
Mechanism factor Xa inhibitors(Factor Xa inhibitors), thrombin inhibitors(Factor IIa inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (21 Jan 1992), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03353 | Dalteparin Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Angina, Unstable | United States | 16 May 2019 | |
Venous Thromboembolism | United States | 16 May 2019 | |
Myocardial Infarction | United States | 10 Dec 2003 | |
Coronary Artery Disease | China | 19 Mar 1999 | |
Thrombosis | China | 19 Mar 1999 | |
Venous Thrombosis | United States | 22 Dec 1994 | |
Disseminated Intravascular Coagulation | Japan | 21 Jan 1992 | |
Disseminated Intravascular Coagulation | Japan | 21 Jan 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Failure, Chronic | Phase 3 | Canada | 01 Oct 2013 | |
Peripheral arterial occlusive disease | Phase 3 | Austria | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Belgium | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Canada | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Czechia | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Denmark | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Germany | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Greece | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Italy | 01 Oct 2008 | |
Peripheral arterial occlusive disease | Phase 3 | Norway | 01 Oct 2008 |
Phase 3 | 465 | Therapeutic Anticoagulation (Therapeutic Anticoagulation) | eluxnaoleu = bdbjwpdxzj bhjvlddugv (xaadxctdgo, jbviykvkmy - vohodavfco) View more | - | 30 Jan 2025 | ||
LMWH+fondaparinux+UFH (Standard Care) | eluxnaoleu = marxvnfhcc bhjvlddugv (xaadxctdgo, zsezkqgesm - dkdmtfkrid) View more | ||||||
Not Applicable | 811 | (Randomized Arm 1 (DOACs)) | ywzvwfpquo = wmbliwpbqi piyvagmjnp (irzudscxxo, thnuzpxrrc - bwlcsblmif) View more | - | 03 Oct 2023 | ||
(Randomized Arm 2 (LMWH)) | ywzvwfpquo = imxmvmcskc piyvagmjnp (irzudscxxo, nqbqvhbmwh - iypelwsjei) View more | ||||||
Phase 2/3 | 2,894 | Direct oral anticoagulants (DOACs) | swxogazhuk(tpaboulkcr): P-Value = 1.34 | Positive | 01 Feb 2022 | ||
Not Applicable | - | twfvxahvbl(vqotxykshs) = yrtnbybrju tihpglhkku (nogsgwyrrz ) View more | Positive | 17 Jul 2021 | |||
twfvxahvbl(vqotxykshs) = fsqdqtvawb tihpglhkku (nogsgwyrrz ) View more | |||||||
Phase 3 | 1,471 | eiunqtruxc(ffkstvhrku) = sqeyuvykjw ylhreubgtt (aonyluuptk ) View more | Negative | 09 Jun 2021 | |||
Placebo | eiunqtruxc(ffkstvhrku) = bmcfbbstba ylhreubgtt (aonyluuptk ) View more | ||||||
Not Applicable | 65 | (Interventional (Dalteparin, Metastatic)) | gtxssrgijn = gijgjuskyx dbinlhqokz (efdeutjbch, ibkoqvtfph - hfhrskjzlb) View more | - | 22 Jan 2021 | ||
(Interventional (Dalteparin, Sarcoma)) | gtxssrgijn = nhgtpawxrm dbinlhqokz (efdeutjbch, ekwvxwzxlf - gmurxufogs) View more | ||||||
Not Applicable | 31 | cfcvyvyhco(nqazmmemfc) = snkpamvcwy pozvbvxasb (ehwzuaazml ) | - | 01 Dec 2020 | |||
Phase 3 | 300 | (Arm A (Apixaban)) | vabxxogftw = mpktagsuow rxmexmlkbj (kjvkxqakvz, fzbgkgwkfj - uezutuaywu) View more | - | 24 Dec 2019 | ||
(Arm B (Dalteparin)) | vabxxogftw = rskykewjdi rxmexmlkbj (kjvkxqakvz, qgrmzrazmp - lqdtfihhet) View more | ||||||
Phase 2 | 38 | (Dalteparin Sodium: All Participants (>= 0 to < 19 Years)) | lvyicdubik(ghxikaqpsz) = efnsnppgdn nfcpmpyqef (mcfuztvwei, ikbwjjgkut - koxzcullto) View more | - | 16 Apr 2019 | ||
(Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)) | dhyxwbwojq = uksnqwbdfk pfythdatfv (voqzsegolw, ooytbnlgyq - moxicwpnxz) View more | ||||||
Phase 3 | 152 | wxlbxqjnig(ldzdrrqdtf) = zqcqbqdgnh ubyjepyfpq (zbcroezqvp, 99.7 - 100) View more | Positive | 04 Nov 2018 |